Bolt Biotherapeutics, Inc.
Public company- Headquarters
- REDWOOD CITY, California
- Ticker
- BOLT
- CIK
- 0001641281
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorSheila Gujrathi | Oct 23, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class II director appointed: Sheila Gujrathi
Sheila Gujrathi was named Class II director of Bolt Biotherapeutics, Inc., effective October 23, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 23, 2026Role: Class II director
layoffs from Jul 15, 2024
WARN noticeWARN notice: CA
Bolt Biotherapeutics, Inc. filed a WARN notice with the California WARN list on May 14, 2024 covering 38 workers. The layoffs take effect on Jul 15, 2024.
Source: California WARN list, filed May 14, 2024Site: CA
Workers affected: 38
Last verified Nov 8, 2026